Jazz Pharmaceuticals (JAZZ) Return on Capital Employed (2011 - 2026)
Jazz Pharmaceuticals' quarterly Return on Capital Employed came in at 0.4% in Q1 2026, down 603.0% year-on-year from 0.08% in Q1 2025, and up 91.45% quarter-over-quarter from 4.64% in Q4 2025.
Jazz Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 0.4% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 603.0% year-over-year to 0.4%; the trailing twelve-month figure through Mar 2026 stood at 0.4% (down 603.0% YoY), and the FY2025 full-year result was 4.48%, down 1120.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 0.4%, up from 4.64% in the prior quarter.
- The five-year high for Return on Capital Employed was 6.46% in Q4 2024, with the low at 5.57% in Q3 2025.
- Average Return on Capital Employed over 5 years is 1.67%, with a median of 2.0% recorded in 2023.
- Year-over-year, Return on Capital Employed soared 660 bps in 2023 and sank 1158 bps in 2025.
- Tracing JAZZ's Return on Capital Employed over 5 years: stood at 0.68% in 2022, then soared by 975 bps to 5.93% in 2023, then climbed by 9 bps to 6.46% in 2024, then plunged by 172 bps to 4.64% in 2025, then surged by 91 bps to 0.4% in 2026.
- The last three Return on Capital Employed figures came in at 0.4% (Q1 2026), 4.64% (Q4 2025), and 5.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | -0.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.40% |
| Dec 31, 2025 | -4.64% |
| Sep 30, 2025 | -5.57% |
| Jun 30, 2025 | -3.18% |
| Mar 31, 2025 | 5.63% |
| Dec 31, 2024 | 6.46% |
| Sep 30, 2024 | 6.02% |
| Jun 30, 2024 | 5.73% |
| Mar 31, 2024 | 5.29% |
| Dec 31, 2023 | 5.93% |
| Sep 30, 2023 | 2.00% |
| Jun 30, 2023 | 0.44% |
| Mar 31, 2023 | -0.27% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | 2.48% |
| Jun 30, 2022 | 2.33% |
| Mar 31, 2022 | 0.85% |
| Dec 31, 2021 | 1.47% |
| Sep 30, 2021 | 2.43% |
| Jun 30, 2021 | 5.08% |
| Mar 31, 2021 | 12.38% |
| Dec 31, 2020 | 6.56% |
| Sep 30, 2020 | 4.80% |
| Jun 30, 2020 | 3.88% |
| Mar 31, 2020 | 4.20% |
| Dec 31, 2019 | 10.30% |
| Sep 30, 2019 | 12.82% |
| Jun 30, 2019 | 14.19% |
| Mar 31, 2019 | 13.69% |
| Dec 31, 2018 | 12.30% |
| Sep 30, 2018 | 11.25% |
| Jun 30, 2018 | 9.43% |
| Mar 31, 2018 | 9.95% |
| Dec 31, 2017 | 11.09% |
| Sep 30, 2017 | 11.94% |
| Jun 30, 2017 | 13.22% |
| Mar 31, 2017 | 13.74% |
| Dec 31, 2016 | 12.84% |
| Sep 30, 2016 | 13.47% |
| Jun 30, 2016 | 16.17% |
| Mar 31, 2016 | 16.89% |
| Dec 31, 2015 | 16.02% |
| Sep 30, 2015 | 17.21% |
| Jun 30, 2015 | 14.82% |
| Mar 31, 2015 | 12.35% |
| Dec 31, 2014 | 6.26% |
| Sep 30, 2014 | 5.49% |
| Jun 30, 2014 | 6.22% |
| Mar 31, 2014 | 7.23% |
| Sep 30, 2013 | 16.17% |
| Jun 30, 2013 | 14.35% |
| Mar 31, 2013 | 13.20% |
| Dec 31, 2012 | 11.95% |
| Sep 30, 2012 | 10.96% |
| Jun 30, 2012 | 13.27% |
| Mar 31, 2012 | 30.00% |
| Dec 31, 2011 | 71.89% |
| Sep 30, 2011 | 80.87% |